Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Report Overview

In 2023, the highest incident cases of Glioblastoma Multiforme (GBM) were from China and India. Glioblastoma Multiforme is a fast-growing and aggressive brain tumor. It is also referred to as a grade IV astrocytoma. GBM invades the nearby brain tissue but generally does not spread to distant organs.

There are only a handful of innovator treatment options approved for the treatment of GBM and most conventional marketed drugs are small molecules, which are administered orally. However, the majority of pipeline drugs for the treatment of GBM are biologics

Key Mechanism of Action (Marketed) ·        Genes, Nucleic Acids, and Related Components Inhibitors

·        Biological Factor Inhibitor

·        Enzyme Inhibitor

·        Receptor Agonist

Key Routes of Administration (Marketed) ·        Oral

·        Topical

·        Injection

Key Molecule Type (Marketed) ·        Small Molecule

·        Biologic

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

The Glioblastoma Multiforme Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Glioblastoma Multiforme.

The report also provides actionable insights on the clinical and commercial landscapes of Glioblastoma Multiforme drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.

Key Mechanisms of Action (Pipeline) ·        Enzyme Inhibitor

·        Cytotoxic to Cell

·        Protein and Peptide Inhibitor

·        Receptor Antagonist

·        Receptor Inhibitor

·        Biological Factor Inhibitor

Key Routes of Administration (Pipeline) ·        Injection

·        Oral

·        Topical

·        Suppository

·        Inhalational

Key Molecule Types (Pipeline) ·        Biologics

·        Small Molecules

·        Oligonucleotide

Top Sponsors (Marketed and Pipeline Drugs) ·        National Cancer Institute, the US

·        Novartis AG

·        Duke University

·        Mayo Clinic

·        Celgene Corp

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Glioblastoma Multiforme Marketed Drugs Segmentation by Mechanisms of Action

The key MoA in the marketed drugs for Glioblastoma Multiforme are genes, nucleic acids and related components inhibitors, biological factor inhibitor, enzyme inhibitor, and receptor agonist. The majority of marketed drugs used for GBM were genes, nucleic acids and related components inhibitors in 2023, followed by transporter inhibitor.

Glioblastoma Multiforme Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)

Glioblastoma Multiforme Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)

Buy the Full Report to Know More about the MoA of men Glioblastoma Multiforme Marketed Drugs

Download a Free Report Sample

Glioblastoma Multiforme Marketed Drugs Segmentation by Routes of Administration

Most of the Glioblastoma Multiforme marketed drugs are orally administered. It is followed by injection and topical.

Glioblastoma Multiforme Marketed Drugs Analysis by Routes of Administration, 2023 (%)

Glioblastoma Multiforme Marketed Drugs Analysis by Routes of Administration, 2023 (%)

Buy the Full Report to Know More about the RoA of Glioblastoma Multiforme Marketed Drugs

Download a Free Report Sample

Glioblastoma Multiforme Marketed Drugs Segmentation by Molecule Types

The key molecule types in the marketed drugs for Glioblastoma Multiforme are small molecule and biologic. The majority of marketed drugs for GBM were small molecules in 2023.

Glioblastoma Multiforme Marketed Drugs Analysis by Molecule Types, 2023 (%)

Glioblastoma Multiforme Marketed Drugs Analysis by Molecule Types, 2023 (%)

Buy the Full Report to Know More about the Molecule Types of Glioblastoma Multiforme Marketed Drugs

Download a Free Report Sample

Glioblastoma Multiforme Pipeline Drugs Market Segmentation by Mechanisms of Action

The key MoA in the Pipeline drugs for Glioblastoma Multiforme are enzyme inhibitor, cytotoxic to cell, protein and peptide inhibitor, receptor antagonist, receptor inhibitor, and biological factor inhibitor. In 2023, enzyme inhibitor was the leading MoA for Glioblastoma Multiforme pipeline drugs.

Glioblastoma Multiforme Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)

Glioblastoma Multiforme Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)

Buy the Full Report to Know More about the MoA of Glioblastoma Multiforme Pipeline Drugs

Download a Free Report Sample

Glioblastoma Multiforme Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration for GBM are injection, suppository, topical, inhalational, and oral. The majority of pipeline drugs for GBM were injection therapies, followed by oral drugs in 2023.

Glioblastoma Multiforme Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)

Glioblastoma Multiforme Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)

Buy the Full Report to Know More about the RoA of Glioblastoma Multiforme Pipeline Drugs

Download a Free Report Sample

Glioblastoma Multiforme Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Glioblastoma Multiforme pipeline drugs market are biologics, small molecules, and oligonucleotide. In 2023, the pipeline of drugs for GBM was dominated by biologic molecules type.

Glioblastoma Multiforme Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)

Glioblastoma Multiforme Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)

Buy the Full Report to Know More about the Molecule Types of Glioblastoma Multiforme Pipeline Drugs

Download a Free Report Sample

Glioblastoma Multiforme Marketed and Pipeline Drugs Market – Competitive Landscape

A few of the top sponsors in the Glioblastoma Multiforme marketed and pipeline drugs market are the National Cancer Institute, the US, Novartis AG, Duke University, Mayo Clinic, and Celgene Corp. In 2023, the National Cancer Institute, the US conducted the highest number of completed trials, followed by Novartis AG

Glioblastoma Multiforme marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)

Glioblastoma Multiforme marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)

Buy the Full Report for More Sponsor Insights into the Glioblastoma Multiforme Marketed and Pipeline Drugs Market

Download a Free Report Sample

Segments Covered in the Report

Glioblastoma Multiforme Marketed Drugs Mechanism of Action (Number of Drugs, 2023)

  • Genes, Nucleic Acids, and Related Components Inhibitors
  • Biological Factor Inhibitor
  • Enzyme Inhibitor
  • Receptor Agonist

Glioblastoma Multiforme Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)

  • Injection
  • Oral
  • Topical

Glioblastoma Multiforme Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)

  • Enzyme Inhibitor
  • Cytotoxic to Cell
  • Protein and Peptide Inhibitor
  • Receptor Antagonist
  • Receptor Inhibitor
  • Biological Factor Inhibitor

Glioblastoma Multiforme Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)

  • Injection
  • Oral
  • Topical
  • Suppository
  • Inhalational

Glioblastoma Multiforme Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)

  • Biologics
  • Small Molecules
  • Oligonucleotide

Scope

GlobalData’s GBM: The competitive Landscape in the report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. The other core components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies by reviewing pipeline products and technologies and identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Glioblastoma Multiforme market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glioblastoma Multiforme market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

5.1 Annual Therapy Cost

5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

6.1 Phase III Pipeline Drugs

6.2 Overview by Development Stage

6.3 Overview by Molecule Type

6.4 Overview by Mechanism of Action

6.5 Overview by Route of Administration

6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

7.1 Historical Overview

7.2 Overview by Phase

7.3 Overview by Status

7.4 Overview by Phase for Ongoing and Planned Trials

7.5 Trials with Virtual Components

7.6 Geographic Overview

7.7 Single-Country and Multinational Trials by Region

7.8 Top 20 Sponsors with Breakdown by Phase

7.9 Top 20 Sponsors with Breakdown by Status

7.10 Overview by Endpoint Status

7.11 Overview by Race and Ethnicity

7.12 Enrollment Data

7.13 Top 20 countries for Trial Sites

7.14 Top 20 Sites Globally

7.15 Feasibility Analysis – Geographic Overview

7.16 Feasibility Analysis – Benchmark Models

8 Deals Landscape

8.1 Mergers, Acquisitions, and Strategic Alliances by Region

8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

11.1 Methodology

11.2 Methodology – Sales Forecast

11.3 Methodology – Pricing and Reimbursement

11.4 Methodology – PTSR and LoA Analysis

11.5 About the Authors

11.6 Contact Us

11.7 Disclaimer

Frequently asked questions

Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape standard reports
Currency USD
$3,495

Can be used by individual purchaser only

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape in real time.

  • Access a live Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.